NASDAQ:CFMS - ConforMIS Stock Price, Price Target & More

$1.79 +0.10 (+5.92 %)
(As of 04/22/2018 11:57 AM ET)
Previous Close$1.79
Today's Range$1.70 - $1.82
52-Week Range$1.15 - $5.98
Volume623,612 shs
Average Volume407,489 shs
Market Capitalization$108.91 million
P/E Ratio-1.44
Dividend YieldN/A
Beta1.01

About ConforMIS (NASDAQ:CFMS)

ConforMIS logoConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient's anatomy. The Company's iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient's knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.

Receive CFMS News and Ratings via Email

Sign-up to receive the latest news and ratings for CFMS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CFMS
CUSIPN/A
Phone781-345-9001

Debt

Debt-to-Equity Ratio0.64%
Current Ratio5.41%
Quick Ratio4.70%

Price-To-Earnings

Trailing P/E Ratio-1.44
Forward P/E Ratio-2.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$78.11 million
Price / Sales1.39
Cash FlowN/A
Price / CashN/A
Book Value$1.02 per share
Price / Book1.75

Profitability

EPS (Most Recent Fiscal Year)($1.24)
Net Income$-53,580,000.00
Net Margins-68.59%
Return on Equity-85.24%
Return on Assets-50.08%

Miscellaneous

Employees350
Outstanding Shares60,840,000

How to Become a New Pot Stock Millionaire

ConforMIS (NASDAQ:CFMS) Frequently Asked Questions

What is ConforMIS's stock symbol?

ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."

How were ConforMIS's earnings last quarter?

ConforMIS (NASDAQ:CFMS) announced its earnings results on Wednesday, February, 7th. The medical instruments supplier reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The medical instruments supplier earned $20.80 million during the quarter, compared to analysts' expectations of $20.07 million. ConforMIS had a negative net margin of 68.59% and a negative return on equity of 85.24%. The firm's quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.37) earnings per share. View ConforMIS's Earnings History.

When is ConforMIS's next earnings date?

ConforMIS is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for ConforMIS.

What price target have analysts set for CFMS?

7 brokerages have issued twelve-month price targets for ConforMIS's shares. Their predictions range from $4.00 to $7.50. On average, they anticipate ConforMIS's stock price to reach $4.75 in the next twelve months. View Analyst Ratings for ConforMIS.

What are Wall Street analysts saying about ConforMIS stock?

Here are some recent quotes from research analysts about ConforMIS stock:
  • 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (4/18/2018)
  • 2. Canaccord Genuity analysts commented, "We recently had the opportunity to host a fireside chat with ConforMIS management as well as visit the company’s booth at AAOS. Overall, we came away incrementally positive on the opportunities ahead of ConforMIS and continue to think commercial momentum through the H1/18 could represent an inflection point in the business. Specifically, we think the commercial changes implemented mid-2017, including new leadership, sales rep hiring, and the build-out of a corporate accounts team position the company with the opportunity for increased productivity into the H2/18. From our recent meetings with management, we highlight additional clinical data that bolsters the company’s implant technology and a strong product pipeline that should support market momentum over the next several years." (3/12/2018)

Who are some of ConforMIS's key competitors?

Who are ConforMIS's key executives?

ConforMIS's management team includes the folowing people:
  • Kenneth Fallon III, Independent Chairman of the Board (Age 77)
  • Mark A. Augusti, President, Chief Executive Officer, Director (Age 51)
  • Paul S. Weiner, Chief Financial Officer (Age 53)
  • Dan Krupp, Senior Vice President - U.S. Sales
  • Daniel Steines M.D., Chief Technology Officer (Age 48)
  • David Cerveny, Chief Legal Officer and General Counsel (Age 50)
  • Philipp Lang M.D., Director (Age 54)
  • Bradley R. Langdale, Independent Director (Age 52)
  • Colm C. Lanigan, Independent Director (Age 51)
  • Richard J. Meelia, Independent Director (Age 68)

When did ConforMIS IPO?

(CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Has ConforMIS been receiving favorable news coverage?

Media stories about CFMS stock have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ConforMIS earned a coverage optimism score of 0.07 on Accern's scale. They also assigned news coverage about the medical instruments supplier an impact score of 46.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of ConforMIS?

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ConforMIS's stock price today?

One share of CFMS stock can currently be purchased for approximately $1.79.

How big of a company is ConforMIS?

ConforMIS has a market capitalization of $108.91 million and generates $78.11 million in revenue each year. The medical instruments supplier earns $-53,580,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. ConforMIS employs 350 workers across the globe.

How can I contact ConforMIS?

ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]


MarketBeat Community Rating for ConforMIS (CFMS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  380
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ConforMIS (NASDAQ:CFMS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for ConforMIS in the last 12 months. Their average twelve-month price target is $4.75, suggesting that the stock has a possible upside of 165.36%. The high price target for CFMS is $7.50 and the low price target for CFMS is $4.00. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldHoldHold
Consensus Rating Score: 2.572.432.332.33
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.75$4.75$5.70$7.10
Price Target Upside: 165.36% upside220.95% upside120.08% upside89.33% upside

ConforMIS (NASDAQ:CFMS) Consensus Price Target History

Price Target History for ConforMIS (NASDAQ:CFMS)

ConforMIS (NASDAQ:CFMS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2018Canaccord GenuityUpgradeHold -> Buy$4.00HighView Rating Details
3/22/2018OppenheimerReiterated RatingBuyHighView Rating Details
2/21/2018CowenInitiated CoverageOutperform$1.39 -> $4.00HighView Rating Details
1/10/2018BTIG ResearchReiterated RatingBuy$4.00LowView Rating Details
1/2/2018JPMorgan ChaseDowngradeNeutral -> UnderweightMediumView Rating Details
8/4/2017Deutsche BankReiterated RatingBuy -> Hold$6.00 -> $5.00HighView Rating Details
5/16/2017B. RileyReiterated RatingBuy$7.50LowView Rating Details
9/19/2016SunTrust BanksInitiated CoverageBuy$14.00N/AView Rating Details
5/13/2016Wells FargoDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

ConforMIS (NASDAQ:CFMS) Earnings History and Estimates Chart

Earnings by Quarter for ConforMIS (NASDAQ:CFMS)

ConforMIS (NASDAQ:CFMS) Earnings Estimates

2018 EPS Consensus Estimate: ($1.03)
2019 EPS Consensus Estimate: ($0.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.34)($0.24)($0.28)
Q2 20183($0.34)($0.21)($0.26)
Q3 20183($0.34)($0.20)($0.25)
Q4 20183($0.34)($0.17)($0.24)
Q1 20191($0.17)($0.17)($0.17)
Q2 20191($0.16)($0.16)($0.16)
Q3 20191($0.16)($0.16)($0.16)
Q4 20191($0.15)($0.15)($0.15)

ConforMIS (NASDAQ CFMS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.27)N/AView Earnings Details
2/7/2018Q4 2017($0.30)($0.27)$20.07 million$20.80 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.32)($0.29)$17.55 million$18.40 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.36)($0.28)$19.34 million$18.50 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.36)($0.40)$18.48 million$20.50 millionViewN/AView Earnings Details
2/15/2017Q416($0.30)($0.37)$21.37 million$21.70 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.31)$18.27 million$18.60 millionViewListenView Earnings Details
8/8/2016Q216($0.35)($0.34)$18.02 million$19.30 millionViewListenView Earnings Details
5/12/2016Q116($0.38)($0.37)$19.23 million$20.30 millionViewListenView Earnings Details
2/11/2016Q415($0.41)($0.37)$17.23 million$19.10 millionViewListenView Earnings Details
11/2/2015Q3($0.38)($0.45)$13.51 million$13.90 millionViewN/AView Earnings Details
8/11/2015Q215($1.31)($2.51)$11.20 million$19.20 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ConforMIS (NASDAQ:CFMS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ConforMIS (NASDAQ CFMS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.59%
Institutional Ownership Percentage: 22.98%
Insider Trading History for ConforMIS (NASDAQ:CFMS)
Institutional Ownership by Quarter for ConforMIS (NASDAQ:CFMS)

ConforMIS (NASDAQ CFMS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/6/2018Daniel SteinesInsiderSell3,632$1.30$4,721.60142,963View SEC Filing  
2/6/2018Paul S WeinerCFOSell2,674$1.30$3,476.20157,009View SEC Filing  
2/6/2018Philipp LangDirectorSell3,737$1.30$4,858.10590,375View SEC Filing  
12/19/2017David CervenyInsiderSell5,478$2.27$12,435.06152,073View SEC Filing  
12/19/2017Mark A AugustiCEOSell16,548$2.27$37,563.96285,007View SEC Filing  
12/19/2017Paul S WeinerCFOSell7,433$2.27$16,872.91167,116View SEC Filing  
12/5/2017Mark A AugustiCEOSell4,189$2.68$11,226.52236,163View SEC Filing  
11/15/2017Daniel SteinesCTOSell15,485$3.15$48,777.75254,652View SEC Filing  
11/15/2017David CervenyInsiderSell16,392$3.17$51,962.64151,408View SEC Filing  
11/15/2017Paul S WeinerCFOSell17,723$3.17$56,181.91162,009View SEC Filing  
10/18/2017Daniel SteinesCTOSell907$3.51$3,183.57254,652View SEC Filing  
10/18/2017Philipp LangDirectorSell1,839$3.53$6,491.67594,112View SEC Filing  
6/20/2017Bradley LangdaleDirectorSell6,722$4.30$28,904.6026,533View SEC Filing  
4/26/2017Daniel SteinesInsiderSell5,000$5.54$27,700.00190,745View SEC Filing  
4/5/2017Daniel SteinesInsiderSell5,000$5.00$25,000.00195,745View SEC Filing  
2/15/2017Philipp LangDirectorSell137,968$8.60$1,186,524.80558,759View SEC Filing  
2/3/2017David CervenyInsiderSell3,569$8.59$30,657.7187,501View SEC Filing  
2/3/2017Paul S WeinerCFOSell2,676$8.42$22,531.9282,115View SEC Filing  
2/3/2017Philipp LangDirectorSell108,705$8.60$934,863.00519,411View SEC Filing  
1/25/2017Philipp LangDirectorSell108,985$8.60$937,271.00558,153View SEC Filing  
1/23/2017Philipp LangDirectorSell9,681$8.60$83,256.60519,784View SEC Filing  
1/13/2017Philipp LangDirectorSell37,275$8.60$320,565.00514,769View SEC Filing  
1/11/2017Philipp LangDirectorSell2,800$8.62$24,136.00516,019View SEC Filing  
1/10/2017Philipp LangDirectorSell83,909$8.64$724,973.76516,119View SEC Filing  
1/9/2017Philipp LangDirectorSell6,200$8.65$53,630.00516,119View SEC Filing  
1/5/2017Philipp LangDirectorSell400$8.60$3,440.00514,719View SEC Filing  
1/3/2017Philipp LangDirectorSell74,876$8.00$599,008.00589,495View SEC Filing  
12/30/2016Philipp LangDirectorSell168,734$8.25$1,392,055.50547,639View SEC Filing  
12/28/2016Philipp LangDirectorSell58,547$8.26$483,598.22532,981View SEC Filing  
12/27/2016Philipp LangDirectorSell42,086$8.57$360,677.02520,939View SEC Filing  
12/23/2016Philipp LangDirectorSell30,647$8.62$264,177.14520,939View SEC Filing  
10/17/2016Daniel SteinesInsiderSell889$8.64$7,680.96214,324View SEC Filing  
10/17/2016Paul S WeinerCFOSell884$8.60$7,602.4084,791View SEC Filing  
10/12/2016Daniel SteinesInsiderSell10,000$9.66$96,600.00215,213View SEC Filing  
10/5/2016Philipp LangCEOSell53,860$10.19$548,833.40483,378View SEC Filing  
10/4/2016Philipp LangCEOSell400$10.00$4,000.00483,378View SEC Filing  
10/3/2016Daniel SteinesCTOSell10,000$10.03$100,300.00225,213View SEC Filing  
10/3/2016Philipp LangCEOSell10,410$10.03$104,412.30483,378View SEC Filing  
9/16/2016Daniel SteinesInsiderSell30,000$9.09$272,700.00245,213View SEC Filing  
8/17/2016Kenneth P Fallon IIIDirectorSell4,000$8.44$33,760.0092,222View SEC Filing  
5/17/2016Robert Law IIISVPBuy1,600$6.20$9,920.0024,793View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ConforMIS (NASDAQ CFMS) News Headlines

Source:
DateHeadline
ConforMISs (CFMS) "Hold" Rating Reiterated at BTIG ResearchConforMIS's (CFMS) "Hold" Rating Reiterated at BTIG Research
www.americanbankingnews.com - April 20 at 2:25 PM
ConforMIS (CFMS) Downgraded to Sell at Zacks Investment ResearchConforMIS (CFMS) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 9:10 PM
Conformis to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 2, 2018Conformis to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 2, 2018
finance.yahoo.com - April 12 at 5:51 PM
$19.51 Million in Sales Expected for ConforMIS (CFMS) This Quarter$19.51 Million in Sales Expected for ConforMIS (CFMS) This Quarter
www.americanbankingnews.com - April 12 at 5:19 AM
Benzingas Top Upgrades, Downgrades For April 10, 2018Benzinga's Top Upgrades, Downgrades For April 10, 2018
www.benzinga.com - April 10 at 5:46 PM
UPDATE: Canaccord Genuity Upgrades ConforMIS (CFMS) to BuyUPDATE: Canaccord Genuity Upgrades ConforMIS (CFMS) to Buy
www.streetinsider.com - April 10 at 5:46 PM
ConforMIS (CFMS) Rating Increased to Buy at Canaccord GenuityConforMIS (CFMS) Rating Increased to Buy at Canaccord Genuity
www.americanbankingnews.com - April 10 at 8:29 AM
-$0.26 EPS Expected for ConforMIS (CFMS) This Quarter-$0.26 EPS Expected for ConforMIS (CFMS) This Quarter
www.americanbankingnews.com - April 10 at 3:13 AM
ConforMIS Inc (CFMS) Given Average Rating of "Hold" by BrokeragesConforMIS Inc (CFMS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 9:58 AM
ConforMIS (CFMS) Cut to Hold at Zacks Investment ResearchConforMIS (CFMS) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 3 at 8:45 PM
ConforMIS (CFMS) Rating Lowered to Strong Sell at ValuEngineConforMIS (CFMS) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 3 at 5:52 PM
ConforMIS (CFMS) Stock Rating Upgraded by Zacks Investment ResearchConforMIS (CFMS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 2 at 8:40 PM
ConforMIS (CFMS) Given Hold Rating at BTIG ResearchConforMIS (CFMS) Given Hold Rating at BTIG Research
www.americanbankingnews.com - April 2 at 8:39 AM
JPMorgan Chase Downgrades ConforMIS (CFMS) to UnderweightJPMorgan Chase Downgrades ConforMIS (CFMS) to Underweight
www.americanbankingnews.com - March 31 at 11:54 AM
Market Trends Toward New Normal in ConforMIS, Equity Commonwealth, SendGrid, Granite Point Mortgage Trust, Stewart Information Services, and South State — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in ConforMIS, Equity Commonwealth, SendGrid, Granite Point Mortgage Trust, Stewart Information Services, and South State — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - March 30 at 8:03 AM
ConforMIS Inc (CFMS) Expected to Post Quarterly Sales of $19.51 MillionConforMIS Inc (CFMS) Expected to Post Quarterly Sales of $19.51 Million
www.americanbankingnews.com - March 26 at 7:53 AM
ConforMIS (CFMS) Earns "Buy" Rating from OppenheimerConforMIS (CFMS) Earns "Buy" Rating from Oppenheimer
www.americanbankingnews.com - March 22 at 4:09 PM
ConforMIS (CFMS) Upgraded to "Buy" by Zacks Investment ResearchConforMIS (CFMS) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:16 PM
ConforMISs (CFMS) "Hold" Rating Reiterated at Canaccord GenuityConforMIS's (CFMS) "Hold" Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - March 12 at 9:22 PM
Quotidian Technical Highlights on Selected Medical Supplies Stocks -- Baxter, ConforMIS, DENTSPLY SIRONA, and ... - PR Newswire (press release)Quotidian Technical Highlights on Selected Medical Supplies Stocks -- Baxter, ConforMIS, DENTSPLY SIRONA, and ... - PR Newswire (press release)
www.prnewswire.com - March 12 at 6:58 AM
ConforMIS Inc (CFMS) Given Consensus Rating of "Hold" by AnalystsConforMIS Inc (CFMS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 10 at 7:36 AM
Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the ... - GlobeNewswire (press release)Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the ... - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:20 AM
Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the Conformis iTotal CRFour-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the Conformis iTotal CR
finance.yahoo.com - March 7 at 8:20 AM
Conformis iTotal CR Knee Replacement System Awarded “3A” Rating from the Orthopaedic Data Evaluation Panel in ... - GlobeNewswire (press release)Conformis iTotal CR Knee Replacement System Awarded “3A” Rating from the Orthopaedic Data Evaluation Panel in ... - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:24 AM
Conformis iTotal CR Knee Replacement System Awarded “3A” Rating from the Orthopaedic Data Evaluation Panel in the United KingdomConformis iTotal CR Knee Replacement System Awarded “3A” Rating from the Orthopaedic Data Evaluation Panel in the United Kingdom
finance.yahoo.com - March 1 at 8:24 AM
ConforMIS (CFMS) Coverage Initiated by Analysts at CowenConforMIS (CFMS) Coverage Initiated by Analysts at Cowen
www.americanbankingnews.com - February 21 at 10:59 AM
ConforMIS Inc (CFMS) Expected to Announce Quarterly Sales of $19.51 MillionConforMIS Inc (CFMS) Expected to Announce Quarterly Sales of $19.51 Million
www.americanbankingnews.com - February 20 at 11:44 AM
Zacks: Brokerages Anticipate ConforMIS Inc (CFMS) to Announce -$0.25 Earnings Per ShareZacks: Brokerages Anticipate ConforMIS Inc (CFMS) to Announce -$0.25 Earnings Per Share
www.americanbankingnews.com - February 18 at 5:08 AM
Active-Investors: Blog Exposure - Becton, Dickinsons New HPV Test BD Onclarity HPV Assay Gets FDA ApprovalActive-Investors: Blog Exposure - Becton, Dickinson's New HPV Test BD Onclarity HPV Assay Gets FDA Approval
www.finanznachrichten.de - February 15 at 5:33 PM
Blog Exposure - Becton, Dickinson’s New HPV Test BD Onclarity(TM) HPV Assay Gets FDA ApprovalBlog Exposure - Becton, Dickinson’s New HPV Test BD Onclarity(TM) HPV Assay Gets FDA Approval
finance.yahoo.com - February 15 at 7:42 AM
ConforMIS Inc (CFMS) Given Consensus Recommendation of "Hold" by BrokeragesConforMIS Inc (CFMS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 13 at 11:20 AM
Zacks Investment Research Upgrades ConforMIS (CFMS) to HoldZacks Investment Research Upgrades ConforMIS (CFMS) to Hold
www.americanbankingnews.com - February 12 at 7:18 PM
Brokers Set Expectations for ConforMIS Incs FY2018 Earnings (CFMS)Brokers Set Expectations for ConforMIS Inc's FY2018 Earnings (CFMS)
www.americanbankingnews.com - February 12 at 6:36 AM
ConforMIS Inc (CFMS) Short Interest Down 30.3% in JanuaryConforMIS Inc (CFMS) Short Interest Down 30.3% in January
www.americanbankingnews.com - February 12 at 4:32 AM
SunTrust Banks Brokers Increase Earnings Estimates for ConforMIS Inc (CFMS)SunTrust Banks Brokers Increase Earnings Estimates for ConforMIS Inc (CFMS)
www.americanbankingnews.com - February 12 at 2:52 AM
ConforMIS Inc (CFMS) Forecasted to Post Q1 2018 Earnings of ($0.24) Per ShareConforMIS Inc (CFMS) Forecasted to Post Q1 2018 Earnings of ($0.24) Per Share
www.americanbankingnews.com - February 9 at 8:52 AM
Oppenheimer Analysts Give ConforMIS (CFMS) a $4.00 Price TargetOppenheimer Analysts Give ConforMIS (CFMS) a $4.00 Price Target
www.americanbankingnews.com - February 8 at 11:14 PM
Should ConforMIS Inc’s (NASDAQ:CFMS) Recent Earnings Worry You?Should ConforMIS Inc’s (NASDAQ:CFMS) Recent Earnings Worry You?
finance.yahoo.com - February 8 at 3:30 PM
ConforMIS Reports Fourth Quarter and the Year Ended 2017 Financial Results; Reiterates 2018 Financial GuidanceConforMIS Reports Fourth Quarter and the Year Ended 2017 Financial Results; Reiterates 2018 Financial Guidance
finance.yahoo.com - February 8 at 3:30 PM
ConforMIS (CFMS) PT Lowered to $4.00ConforMIS (CFMS) PT Lowered to $4.00
www.americanbankingnews.com - February 8 at 1:30 PM
ConforMIS (CFMS) Announces  Earnings Results, Beats Estimates By $0.03 EPSConforMIS (CFMS) Announces Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - February 8 at 9:56 AM
ConforMIS Reports Fourth Quarter and the Year Ended 2017 Financial Results; Reiterates 2018 Financial Guidance - GlobeNewswire (press release)ConforMIS Reports Fourth Quarter and the Year Ended 2017 Financial Results; Reiterates 2018 Financial Guidance - GlobeNewswire (press release)
globenewswire.com - February 8 at 7:30 AM
ConforMIS (CFMS) CEO Mark Augusti on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaConforMIS' (CFMS) CEO Mark Augusti on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 8 at 7:30 AM
ConforMIS (CFMS) Scheduled to Post Quarterly Earnings on TuesdayConforMIS (CFMS) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 6 at 3:12 AM
ConforMIS Inc (CFMS) Prices 13.33M Shares Common Offering at $1.50/Sh - StreetInsider.comConforMIS Inc (CFMS) Prices 13.33M Shares Common Offering at $1.50/Sh - StreetInsider.com
www.streetinsider.com - January 27 at 7:31 AM
ConforMIS Inc (CFMS) Prices 13.33M Shares Common Offering at $1.50/ShConforMIS Inc (CFMS) Prices 13.33M Shares Common Offering at $1.50/Sh
www.streetinsider.com - January 26 at 3:31 PM
BRIEF-Conformis Announces Pricing Of Public Offering Of Common StockBRIEF-Conformis Announces Pricing Of Public Offering Of Common Stock
www.reuters.com - January 25 at 3:32 PM
ConforMISs stock plunges on heavy volume after stock offering prices at deep discountConforMIS's stock plunges on heavy volume after stock offering prices at deep discount
finance.yahoo.com - January 25 at 3:32 PM
ConforMIS Announces Pricing of Public Offering of Common StockConforMIS Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 25 at 3:32 PM
ConforMIS Inc (CFMS) Announces Proposed Common Share OfferingConforMIS Inc (CFMS) Announces Proposed Common Share Offering
www.streetinsider.com - January 25 at 7:36 AM

SEC Filings

ConforMIS (NASDAQ:CFMS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ConforMIS (NASDAQ:CFMS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ConforMIS (NASDAQ CFMS) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.